2008年

December 24, 2008: Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
October 1, 2008: Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
September 30, 2008: Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
August 20, 2008: Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
April 22, 2008: Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
April 18, 2008: Launch of KIPRES Tablets 5mg
March 3, 2008: Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
February 21, 2008: Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
January 30, 2008: Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
January 25, 2008: KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis